| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,280,000 |
| Market
Cap: |
80.98(M) |
| Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,713 |
| 52
Week Range: |
$2.25 - $7.96 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.6 |
| Insider 6 Months : 14.8 |
| Insider 3/6 Months : 23.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53,764 |
357,764 |
382,819 |
561,734 |
| Total Buy Value |
$200,002 |
$981,272 |
$1,081,809 |
$1,756,761 |
| Total People Bought |
2 |
6 |
8 |
9 |
| Total Buy Transactions |
2 |
8 |
10 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simpson Jennifer K. |
President and CEO |
• • – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,310 |
10,321 |
|
- |
|
| Keck Barbra |
See Remarks |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,040 |
6,051 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2020-05-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
185,000 |
|
45% |
|
| Rosalind Advisors, Inc. |
Director |
– • – |
2020-05-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
185,000 |
|
45% |
|
| Salamon Steven A J |
Director |
– • – |
2020-05-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
185,000 |
|
45% |
|
| Simpson Jennifer K. |
President & CEO |
• – – |
2018-09-28 |
4 |
B |
$1.75 |
$12,948 |
D/D |
7,399 |
7,500 |
2.74 |
- |
|
| Rueckert William Dodge |
Director |
– • – |
2018-09-28 |
4 |
B |
$1.75 |
$11,375 |
D/D |
6,500 |
7,926 |
2.39 |
- |
|
| Purpura John |
EVP, Global Operations |
• – – |
2018-09-28 |
4 |
B |
$1.75 |
$9,625 |
D/D |
5,500 |
5,501 |
2.74 |
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2018-09-28 |
4 |
B |
$1.75 |
$8,575 |
D/D |
4,900 |
5,901 |
2.39 |
- |
|
| Keck Barbra |
Chief Financial Officer |
• – – |
2018-09-28 |
4 |
B |
$1.75 |
$12,948 |
D/D |
7,399 |
7,500 |
2.74 |
- |
|
| Keck Barbra |
Chief Financial Officer |
• – – |
2018-08-01 |
4 |
B |
$2.39 |
$239 |
D/D |
100 |
101 |
2.66 |
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2018-08-01 |
4 |
B |
$2.36 |
$2,466 |
D/D |
1,000 |
1,001 |
2.31 |
- |
|
| Simpson Jennifer K. |
President & CEO |
• – – |
2018-07-31 |
4 |
B |
$2.55 |
$255 |
D/D |
100 |
101 |
2.66 |
- |
|
| Rueckert William Dodge |
Director |
– • – |
2018-07-31 |
4 |
B |
$2.50 |
$8,103 |
D/D |
3,208 |
3,209 |
2.39 |
- |
|
| Simpson Jennifer K. |
President & CEO |
• – – |
2017-06-27 |
4 |
D |
$0.22 |
$102 |
D/D |
(468) |
41,908 |
|
- |
|
| Keck Barbra |
Chief Financial Officer |
• – – |
2017-06-27 |
4 |
D |
$0.22 |
$37 |
D/D |
(168) |
23,887 |
|
- |
|
| Purpura John |
EVP, Regulatory Affairs |
• – – |
2017-06-27 |
4 |
D |
$0.22 |
$50 |
D/D |
(230) |
35,398 |
|
- |
|
| Keck Barbra |
Senior VP, Finance |
• – – |
2017-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
24,055 |
|
- |
|
| Purpura John |
EVP, Regulatory Affairs |
• – – |
2016-06-16 |
4 |
D |
$0.25 |
$2,935 |
D/D |
(11,738) |
90,074 |
|
- |
|
| Keck Barbra |
Senior VP, Finance |
• – – |
2016-06-16 |
4 |
D |
$0.25 |
$2,140 |
D/D |
(8,561) |
64,926 |
|
- |
|
| Simpson Jennifer K. |
President & CEO |
• – – |
2016-06-16 |
4 |
D |
$0.25 |
$6,001 |
D/D |
(24,004) |
178,292 |
|
- |
|
| Taglietti Marco |
Director |
– • – |
2015-07-28 |
4 |
B |
$0.53 |
$54,433 |
I/I |
100,000 |
220,000 |
2.1 |
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2015-07-27 |
4 |
B |
$0.54 |
$10,740 |
D/D |
20,000 |
99,145 |
2.39 |
- |
|
| Taglietti Marco |
Director |
– • – |
2015-07-27 |
4 |
B |
$0.52 |
$52,350 |
I/I |
100,000 |
120,000 |
2.1 |
- |
|
| Philips Laura A |
Director |
– • – |
2015-07-23 |
4 |
B |
$0.50 |
$45,333 |
D/D |
91,011 |
205,299 |
2.39 |
- |
|
118 Records found
|
|
Page 4 of 5 |
|
|
0.04 (0.76%) 
